WHWK
Whitehawk Therapeutics Inc
There isn't enough reported data to score WHWK yet.
WHWK Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
WHWK's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
WHWK PE Valuation
WHWK has no meaningful PE right now: it lost money over the past year.
WHWK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect WHWK's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
WHWK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.89 | -1554% |
| Q2 2026 | -$1.92 | -$1.85 |
| Q1 2026 | -$2.48 | -1753% |
| Q4 2025 | -$0.33 | +$2.03 |
| Q3 2025 | $0.13 | +$2.41 |
| Q2 2025 | -$0.07 | +$2.35 |
| Q1 2025 | $0.15 | +$2.70 |
| Q4 2024 | -$2.36 | +$0.08 |
WHWK has swung to a loss: it lost $1.89 per share over the past year, after a profit the year before.
WHWK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2025 | $7.1M | +33% |
| Q4 2024 | $7.2M | +14% |
| Q3 2024 | $7.2M | +21% |
| Q2 2024 | $6.2M | -0.4% |
| Q1 2024 | $5.4M | -8.8% |
| Q4 2023 | $6.3M | +21% |
| Q3 2023 | $6M | +40% |
| Q2 2023 | $6.2M | +80% |
WHWK's revenue has slid since its 2020 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2025 | -213% | +152 points |
| Q4 2024 | -262% | +18 points |
| Q3 2024 | -186% | +114 points |
| Q2 2024 | -252% | +63 points |
| Q1 2024 | -365% | -78 points |
| Q4 2023 | -280% | +16 points |
| Q3 2023 | -300% | +55 points |
| Q2 2023 | -315% | +219 points |
WHWK's operating margin was −213% last quarter, up 152 points from the same quarter a year ago.
WHWK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$19.7M | -$4.3M |
| Q2 2026 | -$14.5M | +$38.4M |
| Q1 2026 | -$22.2M | -$9.8M |
| Q4 2025 | -$17.2M | -$2M |
| Q3 2025 | -$15.4M | +$497K |
| Q2 2025 | -$53M | -$43.3M |
| Q1 2025 | -$12.4M | +$8M |
| Q4 2024 | -$15.2M | -$4.8M |
WHWK has burned cash in almost every quarter: −$74M over the past year, against −$96M the year before.
WHWK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +13% | +11M shares |
| 1 year | +36% | +24.8M shares |
| 3 years | +249% | +67M shares |
| 5 years | +3203% | +91M shares |
| Available history | +3369% | +91.2M shares |
WHWK has 94M diluted shares, up 36% from a year ago.
WHWK Net Leverage
WHWK's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
WHWK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.5 | Neutral |
| Stochastic | 13.2 | Oversold |
WHWK's weekly RSI is 40 (neutral) and its Stochastic is 13 (oversold).
WHWK PE vs Healthcare Sector
| Metric | WHWK | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
WHWK has no meaningful PE right now: it lost money over the past year.
WHWK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.31 | 7.3% below |
| 20 week MA | $3.88 | 21% below |
| 50 week MA | $3.63 | 15% below |
| 100 week MA | $2.89 | 6.2% above |
| 200 week MA | $3.60 | 15% below |
WHWK's trend is mixed: it's above one of its five weekly moving averages, and 15% below its 200-week average.
WHWK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $26.0 | $25.9 | -0.6% |
| 2022 | $25.9 | $12.5 | -52% |
| 2023 | $12.5 | $2.02 | -84% |
| 2024 | $2.02 | $3.21 | +59% |
| 2025 | $3.21 | $2.67 | -17% |
| 2026 YTD | $2.67 | $3.07 | +15% |
WHWK has finished lower in four of the last five years. It's up 15% so far in 2026.